scholarly journals The Effect of Birch Pollen Immunotherapy on Apple and rMal d 1 Challenges in Adults with Apple Allergy

Nutrients ◽  
2020 ◽  
Vol 12 (2) ◽  
pp. 519 ◽  
Author(s):  
Johanna van der Valk ◽  
Birgit Nagl ◽  
Roy Gerth van Wljk ◽  
Barbara Bohle ◽  
Nicolette de Jong
Keyword(s):  
Skin Prick Test ◽  
Challenge Test ◽  
Birch Pollen ◽  
Food Challenge ◽  
Specific Ige ◽  
P Value ◽  
Double Blind ◽  
P Values ◽  
Prick Test ◽  
Bet V 1

Background: A proportion of patients allergic to birch pollen are also allergic to pit fruit. The objective of this study was to investigate the effect of immunotherapy with birch pollen on birch-pollen-related apple allergy. Method: Patients with birch pollen immunotherapy underwent a skin-prick test with birch pollen, apple and rMal d 1, global assessments and nasal challenges with birch pollen, open food challenge with apple and a double-blind, placebo-controlled test with rMal d 1 at the start of and during the immunotherapy. Measurements of specific IgE in response to Bet v 1 and rMal d 1 and IgG4 in response to Bet v 1 and rMal d 1 took place. Results: Six of eight patients demonstrated an improvement of nasal challenge test results and all patients improved on global assessment during the immunotherapy. The median oral dose of apple required to elicit a reaction increased but was not statistically significant. The patients showed a decrease in skin-prick test values in response to birch pollen (1.05 to 0.36), apple (0.78 to 0.25) and rMal d 1 (0.51 to 0.10) with p-values of 0.04, 0.03 and 0.06, respectively and a decrease of specific IgE in response to Bet v 1 (10.66 kU/L to 5.19 kU/L) and rMal d 1 (0.99 to 0.61 kU/L) with p-values of 0.01 and 0.05, respectively. Only the median specific IgG4 value to Bet v 1 increased from 0.05 to 1.85 mg/L (p-value of 0.02) and not to IgG4 rMal d 1 (0.07 to 0.08 kU/L). Conclusion: The beneficial effects of immunotherapy for birch pollen were accompanied by a limited effect on apple allergy.

Prediction of challenge test results by flour-specific IgE and skin prick test in symptomatic bakers

Allergy ◽  
2008 ◽  
Vol 63 (7) ◽  
pp. 897-902 ◽  
Author(s):  
V. Van Kampen ◽  
S. Rabstein ◽  
I. Sander ◽  
R. Merget ◽  
T. Brüning ◽  
...  
Keyword(s):  
Skin Prick Test ◽  
Challenge Test ◽  
Specific Ige ◽  
Test Results ◽  
Prick Test

Prediction of anaphylaxis during peanut food challenge: usefulness of the peanut skin prick test (SPT) and specific IgE level

2010 ◽  
Vol 21 (4p1) ◽  
pp. 603-611 ◽  
Author(s):  
Brynn Kevin Wainstein ◽  
Jennie Studdert ◽  
Mary Ziegler ◽  
John B. Ziegler
Keyword(s):  
Skin Prick Test ◽  
Food Challenge ◽  
Specific Ige ◽  
Prick Test ◽  
Peanut Skin

scholarly journals Clinical Outcome of Autologous Serum Therapy in Chronic Idiopathic Urticaria

2017 ◽  
Vol 15 (1) ◽  
pp. 71-74 ◽  
Author(s):  
Dharmendra Karn ◽  
Shekhar KC
Keyword(s):  
Skin Prick Test ◽  
Chronic Urticaria ◽  
Statistical Significance ◽  
Cost Effective ◽  
Chronic Idiopathic Urticaria ◽  
Autologous Serum ◽  
P Value ◽  
Prick Test ◽  
H1 Antihistamines ◽  
Serum Therapy

Background: Quality of life in chronic idiopathic urticaria is hampered as efficacy of H1-antihistamines is limited. Autologous serum containing tolerance-generating anti-idiotype antibodies is a novel and cost-effective therapy. This study was conducted to evaluate the efficacy of autologous serum therapy (AST) among chronic urticaria patients with autologous skin prick test positive and negative status.Methods: Untreated 102 patients of chronic urticaria were enrolled in a non-randomized interventional study. Patients were categorized into two groups based on autologous serum skin prick test as test positive (ASST +) and test negative (ASST -). Patients were then treated with intramuscular injection of 0.05ml per kg body weight of autologous serum weekly for 10 weeks. Urticaria activity scoring (UAS) tool was used for quantification of the symptoms. Weekly recording of UAS (range: 0-42) was made before the therapy (baseline) and during the therapy for 10 weeks.Results: Significant improvement with AST in the mean UAS was noted from baseline to 10 weeks in both the group of patients (14.6 ± 6.3 and 10.2 ± 5.1 for ASST+ group; 16.9 ± 7.8 and 8.6 ± 4.8 for ASST- group; at baseline and 10 weeks, respectively (p-value for both <0.05)). However no statistical significance was found while comparing the efficacy of the therapy against ASST + and ASST - Groups (p-value > 0.05).Conclusions: Irrespective of autologous skin prick test results, autologous serum therapy showed significant improvement in patients with chornic idiopathic urticaria. AST can, thus, be an effective treatment modality for it.

Sign in / Sign up

Export Citation Format

Share Document